Roche/Ipsen's diabetes drug taspoglutide stumbles on safety grounds, meaning delay in approval
The diabetes drug candidate taspoglutide, under development by Swiss drug major Roche and France's Ipsen, has run into a difficulty that could delay its approval for up to a year and a half, despite a string of positive, late-stage clinical results over the past several months (The Pharma Letters passim).
The news saw Ipsen's share price fall as much as 20%, before settling 16% lower at 26.98 euros. Roche dipped 2.3% to 155.3 Swiss francs in morning trading last Friday, when the company announced the implementation of a risk mitigation plan in the taspoglutide Phase III program. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research, and is being developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
Good news for Novo Nordisk
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze